The DOI matches its Crossref record; 325 of the 325 references it cites were found in a registry or an index.
Linking Inflammation, Aberrant Glutamate-Dopamine Interaction, and Post-synaptic Changes: Translational Relevance for Schizophrenia and Antipsychotic Treatment: a Systematic Review
Open accessAbstract
Evidence from clinical, preclinical, and post-mortem studies supports the inflammatory/immune hypothesis of schizophrenia pathogenesis. Less evident is the link between the inflammatory background and two well-recognized functional and structural findings of schizophrenia pathophysiology: the dopamine-glutamate aberrant interaction and the alteration of dendritic spines architecture, both believed to be the "quantal" elements of cortical-subcortical dysfunctional network. In this systematic review, we tried to capture the major findings linking inflammation, aberrant glutamate-dopamine interaction, and post-synaptic changes under a direct and inverse translational perspective, a paramount picture that at present is lacking. The inflammatory effects on dopaminergic function appear to be bidirectional: the inflammation influences dopamine release, and dopamine acts as a regulator of discrete inflammatory processes involved in schizophrenia such as dysregulated interleukin and kynurenine pathways. Furthermore, the link between inflammation and glutamate is strongly supported by clinical studies aimed at exploring overactive microglia in schizophrenia patients and maternal immune activation models, indicating impaired glutamate regulation and reduced N-methyl-D-aspartate receptor (NMDAR) function. In addition, an inflammatory/immune-induced alteration of post-synaptic density scaffold proteins, crucial for downstream NMDAR signaling and synaptic efficacy, has been demonstrated. According to these findings, a significant increase in plasma inflammatory markers has been found in schizophrenia patients compared to healthy controls, associated with reduced cortical integrity and functional connectivity, relevant to the cognitive deficit of schizophrenia. Finally, the link between altered inflammatory/immune responses raises relevant questions regarding potential new therapeutic strategies specifically for those forms of schizophrenia that are resistant to canonical antipsychotics or unresponsive to clozapine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The above neurophysiological mechanisms are also likely highly interactive at multiple explanatory levels; for example, dopamine can regulate inflammatory responses and vice versa, 105 and neuroendocrine stress systems and immune regulation may impact neuronal connectivity and brain function.”
From Towards an Integrative Account of Potential Mechanisms Mediating the Path From Sleep Dysfunction to Hallucinations (2025) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–325 of 325
Hu, X., Zhou, H., Zhang, D., Yang, S., Li, Q., Wu, H.-M., Chen, P.-S., Wilson, B. C., Gao, H., Lu, R., et al. (2011) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-011-9309-0 · Cited by 100
Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects
Muller, N., Myint, A.-M., & J. Schwarz, M. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795049552 · Cited by 94
Critchlow, H., Maycox, P. R., Skepper, J. N., & Krylova, O. Y. (2006) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2006.05.007 · Cited by 93
Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice
Mizoguchi, H., Takuma, K., Fukakusa, A., Ito, Y., Nakatani, A., Ibi, D., Kim, H., & Yamada, K. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0955-0 · Cited by 93
Paul, B. D., & Snyder, S. H. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01315 · Cited by 92
The Cross-Talk Between the Dopaminergic and the Immune System Involved in Schizophrenia
Vidal, P. M., & Pacheco, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00394 · Cited by 92
Perez‐Cruz, C., Keuker, J. I. H., Heilbronner, U., Fuchs, E., & Flügge, G. (2007) · Neural Plasticity · doi:10.1155/2007/46276 · Cited by 91
Impaired regulatory T cell control of astroglial overdrive and microglial pruning in schizophrenia
Zuelli, F. M. D. G. C., & Deakin, J. F. W. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.03.004 · Cited by 90
Schizophrenia as an Immunologic Disorder
Heath, R. G., Krupp, I. M., Byers, L. W., & Liljekvist, J. I. (1967) · Archives of General Psychiatry · doi:10.1001/archpsyc.1967.01730190026003 · Cited by 89
Tucsek, Z., Valcarcel‐Ares, M. N., Tarantini, S., Yabluchanskiy, A., Fülöp, G., Gautam, T., Orock, A. M., Csiszár, A., Deák, F., & Ungvari, Z. I. (2017) · GeroScience · doi:10.1007/s11357-017-9981-y · Cited by 89
Wang, B., Navath, R. S., Romero, R. J., Kannan, S., & Kannan, R. M. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.04.050 · Cited by 87
Ishizuka, K., Fujita, Y., Kawabata, T., Kimura, H., Iwayama, Y., Inada, T., Okahisa, Y., Egawa, J., Usami, M., Kushima, I., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.173 · Cited by 87
Roles for NF-κB and Gene Targets of NF-κB in Synaptic Plasticity, Memory, and Navigation
Snow, W. M., Stoesz, B. M., Kelly, D. M., & Albensi, B. C. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8555-y · Cited by 86
Wolff, A. R., & Bilkey, D. K. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.05.008 · Cited by 84
Musazzi, L., Treccani, G., & Popoli, M. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00060 · Cited by 83
Schwieler, L., Erhardt, S., Erhardt, C., & Engberg, G. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0231-y · Cited by 81
Latent inhibition and schizophrenia: Pavlovian conditioning of autonomic responses
Vaitl, D., Lipp, O. V., Bauer, U., Schüler, G., Stark, R. M., Zimmermann, M., & Kirsch, P. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00250-x · Cited by 81
The role of the ventral dentate gyrus in anxiety-based behaviors
Weeden, C. S. S., Roberts, J. M., Kamm, A. M., & Kesner, R. P. (2015) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2014.12.002 · Cited by 80
Immunological aspects of the treatment of depression and schizophrenia
Müller, N. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.1/nmueller · Cited by 80
de Bartolomeis, A., Barone, A., Begni, V., & Riva, M. A. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106078 · Cited by 79
Self-citationMüller, N. (2014) · NeuroImmunoModulation · doi:10.1159/000356538 · Cited by 78
Corti, C., Xuereb, J. H., Crepaldi, L., Corsi, M., Michielin, F., & Ferraguti, F. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.01.021 · Cited by 77
Cieślik, M., Gąssowska-Dobrowolska, M., Jęśko, H. M., Czapski, G. A., Wilkaniec, A., Zawadzka, A., Dominiak, A., Polowy, R., Filipkowski, R. K., Boguszewski, P. M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114097 · Cited by 77
Regulation of noradrenergic function by inflammatory cytokines and depolarization
Li, W., Knowlton, D. L., Woodward, W. R., & Habecker, B. A. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01890.x · Cited by 74
Norden, D. M., Trojanowski, P. J., Walker, F. R., & Godbout, J. P. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.04.014 · Cited by 73
Aguilar‐Valles, A., Rodrigue, B., & Matta‐Camacho, E. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00852 · Cited by 73
Müller, N., Riedel, M., & Schwarz, M. J. (2004) · Pharmacopsychiatry · doi:10.1055/s-2004-832682 · Cited by 71
Targeting the Dopaminergic System in Autoimmunity
Vidal, P. M., & Pacheco, R. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09834-5 · Cited by 71
Kumarasinghe, N., Beveridge, N. J., Gardiner, E. J., Scott, R. J., Yasawardene, S. G., Perera, A., Mendis, J., Suriyakumara, K., Schall, U., & Tooney, P. A. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000035 · Cited by 70
Perez, S. M., Boley, A. M., & Lodge, D. J. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0603-6 · Cited by 70
Xu, M., & He, L. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.02.1031 · Cited by 68
Brinholi, F. F., de Farias, C. C., Bonifácio, K. L., Higachi, L., Casagrande, R., Moreira, E. G., & Barbosa, D. S. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.02.047 · Cited by 68
Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex
Schwieler, L., Engberg, G., & Erhardt, S. (2004) · Synapse · doi:10.1002/syn.20008 · Cited by 66
Chang, H., Xiao, X., & Li, M. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.19 · Cited by 66
Schizophrenia: A review of potential biomarkers
Rodrígues-Amorím, D., Baltanás, T. R., López, M., Spuch, C., Olivares, J. M., & Agís‐Balboa, R. C. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.05.009 · Cited by 65
Schmitt, A., Leonardi‐Essmann, F., Durrenberger, P. F., Parlapani, E., Schneider-Axmann, T., Spanagel, R., Arzberger, T., Kretzschmar, H. A., Herrera‐Marschitz, M., Gruber, O., et al. (2010) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2010.530690 · Cited by 64
Hui, C. W., Vecchiarelli, H. A., Gervais, É., Luo, X., Michaud, F., Scheefhals, L., Bisht, K., Sharma, K., Topolnik, L., & Tremblay, M.-È. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.558181 · Cited by 64
Gleich, T., Deserno, L., Lorenz, R. C., Boehme, R., Pankow, A., Buchert, R., Kuhn, S., Heinz, A., Schlagenhauf, F., & Gallinat, J. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.0329-15.2015 · Cited by 62
Chen, R., Daining, C. P., Sun, H., Fraser, R., Stokes, S. L., Leitges, M., & Gnegy, M. E. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12229 · Cited by 59
Chávez, C. E., Oyarzún, J. E., Avendaño, B. C., Mellado, L. A., Inostroza, C. A., Alvear, T. F., & Orellana, J. A. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00460 · Cited by 59
Transgenerational modification of dopaminergic dysfunctions induced by maternal immune activation
Weber‐Stadlbauer, U., Richetto, J., Zwamborn, R. A. J., Slieker, R. C., & Meyer, U. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00855-w · Cited by 59
Oh‐Nishi, A., Obayashi, S., Sugihara, I., Minamimoto, T., & Suhara, T. (2010) · Brain Research · doi:10.1016/j.brainres.2010.09.054 · Cited by 57
Felger, J. C., Cole, S. W., Pace, T. W. W., Hu, F., Woolwine, B. J., Doho, G., Raison, C. L., & Miller, A. H. (2011) · Psychological Medicine · doi:10.1017/s0033291711002868 · Cited by 56
Age-related changes in cyclic GMP and PKG-stimulated cerebellar Na,K-ATPase activity
Scavone, C., Munhoz, C. D., Kawamoto, E. M., Glezer, I., Lima, L. D. S., Marcourakis, T., & Markus, R. P. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.08.013 · Cited by 55
de Bartolomeis, A., Manchia, M., Marmo, F., Vellucci, L., Iasevoli, F., & Barone, A. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00369 · Cited by 54
Self-citationIasevoli, F., Tomasetti, C., Buonaguro, E. F., & de Bartolomeis, A. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140324183406 · Cited by 53
Self-citationBenros, M. E., & Mortensen, P. B. (2019) · Current topics in behavioral neurosciences · doi:10.1007/7854_2019_93 · Cited by 53
Yeung, R. K., Xiang, Z., Tsang, S., Li, R., Ho, T. Y. C., Li, Q., Hui, C.-K., Sham, P. C., Qiao, M.-Q., & Xue, H. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0176-9 · Cited by 51
Gos, T., Myint, A.-M., Schiltz, K., Meyer-Lotz, G., Dobrowolny, H., Busse, S., Müller, U. J., Mawrin, C., Bernstein, H.-G., Bogerts, B., et al. (2014) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.05.012 · Cited by 49
Administration of Interleukin‐1 at Birth Affects Dopaminergic Neurons in Adult Mice a
Kabiersch, A., Furukawa, H., del Rey, A., & Besedovsky, H. O. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb09556.x · Cited by 48
Aguilar‐Valles, A., Jung, S., Poole, S., Flores, C., & Luheshi, G. N. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.11.003 · Cited by 47
Eulenburg, V., Retiounskaia, M., Papadopoulos, T. G., et al. (2010) · Glia · doi:10.1002/glia.20987 · Cited by 46
The role of p38 MAPK in valproic acid induced microglia apoptosis
Xie, N., Wang, C., Lin, Y. H., Li, H., Chen, L., Zhang, T., Sun, Y., Zhang, Y., Yin, D., & Chi, Z. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.07.004 · Cited by 45
MacDowell, K. S., Caso, J. R., Martín‐Hernández, D., Madrigal, J. L. M., Leza, J. C., & García‐Bueno, B. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu070 · Cited by 45
Inflammatory cytokine network in schizophrenia
Zakharyan, R., & Boyajyan, A. S. (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.830774 · Cited by 45
Aguilar‐Valles, A., Poole, S., Mistry, Y., Williams, S., & Luheshi, G. N. (2007) · The Journal of Physiology · doi:10.1113/jphysiol.2007.132829 · Cited by 44
Goeden, N., & Bonnin, A. (2012) · Nature Protocols · doi:10.1038/nprot.2012.144 · Cited by 44
Zhao, X., Mohammed, R., Tran, H., Erickson, M., & Kentner, A. C. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.03.018 · Cited by 44
Peripheral complement is increased in schizophrenia and inversely related to cortical thickness
Ji, E., Boerrigter, D., Cai, H. Q., Lloyd, D., Bruggemann, J. M., O׳Donnell, M., Galletly, C. A., Lloyd, A. R., Liu, D., Lenroot, R., et al. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.11.014 · Cited by 44
Chua, J. S. C., Cowley, C. J., Manavis, J., Rofe, A. M., & Coyle, P. V. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.10.002 · Cited by 43
Xiu, M. H., Tian, L., Chen, S., Tan, Y., Chen, D. C., Chen, J., Chen, N., Yang, F. D., Licinio, J., Kosten, T. R., et al. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.03.005 · Cited by 43
Microglial Activation and Psychotic Disorders: Evidence from Pre-clinical and Clinical Studies
Barichello, T., Simões, L. R., Quevedo, J., & Zhang, X. Y. (2019) · Current topics in behavioral neurosciences · doi:10.1007/7854_2018_81 · Cited by 43
Liu, Z., Osipovitch, M., Benraiss, A., Huynh, N. P. T., Foti, R., Bates, J., Chandler-Militello, D., Findling, R. L., Tesar, P. J., Nedergaard, M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.088 · Cited by 43
Nakamura, J., Schroeder, A., Gibbons, A. S., Sundram, S., & Hill, R. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.11.006 · Cited by 43
Fond, G. B., Godin, O., Brunel, L., Aouizerate, B., Berna, F. S., Bulzacka, E., Capdevielle, D., Chéreau, I., Dorey, J., Dubertret, C., et al. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.11.017 · Cited by 42
Horiguchi, M., Hannaway, K. E., Adelekun, A. E., Huang, M., Jayathilake, K., & Meltzer, H. Y. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.09.030 · Cited by 41
Paterson, G., Ohashi, Y., Reynolds, G. P., Pratt, J. A., & MORRIS, B. J. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106062025 · Cited by 41
Chaves, C., Marque, C. R., Maia-de-Oliveira, J. P., Wichert-Ana, L., Ferrari, T. B., Santos, A. C., Araújo, D., Machado-de-Sousa, J. P., Bressan, R. A., Elkis, H., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.11.031 · Cited by 41
Dwir, D., Cabungcal, J.-H., Xin, L., Giangreco, B., Parietti, E., Cleusix, M., Jenni, R., Klauser, P., Conus, P., Cuénod, M., et al. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab066 · Cited by 41
Meade, A. J., Meloni, B. P., Cross, J. L., Bakker, A. J., Fear, M. W., Mastaglia, F. L., Watt, P. M., & Knuckey, N. W. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06459.x · Cited by 40
de Bartolomeis, A., Barone, A., Buonaguro, E. F., Tomasetti, C., Vellucci, L., & Iasevoli, F. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104596 · Cited by 40
Self-citationAguilar‐Valles, A., & Luheshi, G. N. (2010) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.09.006 · Cited by 38
High White Matter Neuron Density with Elevated Cortical Cytokine Expression in Schizophrenia
Fung, S. J., Joshi, D., Fillman, S. G., & Weickert, C. S. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.05.031 · Cited by 38
Tseng, W. C., Reinhart, V., Lanz, T. A., Weber, M. L., Pang, J., Le, K. X., Bell, R. D., O’Donnell, P., & Buhl, D. L. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01262-5 · Cited by 38
Wesseling, H., Rahmoune, H., Tricklebank, M. D., Guest, P. C., & Bahn, S. (2014) · Journal of Proteome Research · doi:10.1021/pr5009493 · Cited by 37
Soares, A. R., Gildawie, K. R., Honeycutt, J. A., & Brenhouse, H. C. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112658 · Cited by 37
Lundberg, M., Curbo, S., Bohman, H., Agartz, I., Ögren, S. O., Patrone, C., & Mansouri, S. (2020) · Bioscience Reports · doi:10.1042/bsr20193156 · Cited by 36
Novaes, L. S., dos Santos, N. B., Dragunas, G., Perfetto, J. G., Leza, J. C., Scavone, C., & Munhoz, C. D. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.09.037 · Cited by 35
Pond, H. L., Heller, A. T., Gural, B. M., McKissick, O. P., Wilkinson, M. K., & Manzini, M. C. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24857 · Cited by 35
Hasam‐Henderson, L. A., Gotti, G. C., Mishto, M., Klisch, C., Gerevich, Z., Geiger, J. R. P., & Kovács, R. (2018) · Scientific Reports · doi:10.1038/s41598-018-27830-2 · Cited by 34
McColl, E. R., & Piquette‐Miller, M. (2019) · American Journal of Reproductive Immunology · doi:10.1111/aji.13115 · Cited by 34
You, M., Bang, M., Park, H., Yang, B., Jang, K. B., Yoo, J., Hwang, D., Kim, M., Kim, B., Lee, S., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0802-1 · Cited by 33
Umeda‐Yano, S., Hashimoto, R., Yamamori, H., Okada, T., Yasuda, Y., Ohi, K., Fukumoto, M., Itô, A., & Takeda, M. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.01.026 · Cited by 32
Arnsten, A. F. T. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1274-9 · Cited by 32
Abnormal microglial reactivity in gray matter of the prefrontal cortex in schizophrenia
Uranova, N. A., Vikhreva, O. V., & Рахманова, В. И. (2021) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2021.102752 · Cited by 32
Mini‐review: Update on the genetics of schizophrenia
Coelewij, L., & Curtis, D. (2018) · Annals of Human Genetics · doi:10.1111/ahg.12259 · Cited by 31
Hao, K., Su, X., Luo, B., Cai, Y., Chen, T., Yang, Y., Shao, M., Song, M., Zhang, L., Zhong, Z., et al. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.111946 · Cited by 31
Silver, H., Susser, E., Danovich, L., Bilker, W. B., Youdim, M. B. H., Goldin, V., & Weinreb, O. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001471 · Cited by 30
Munhoz, C. D., Madrigal, J. L. M., García‐Bueno, B., Pradillo, J. M., Moro, M. Á., Lizasoaín, I., Lorenzo, P. L., Scavone, C., & Leza, J. C. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03560.x · Cited by 30
Dopamine inhibits human CD8+ Treg function through D1-like dopaminergic receptors
Nasi, G., Ahmed, T., Rasini, E., Fenoglio, D., Marino, F., Filaci, G., & Cosentino, M. (2019) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2019.02.007 · Cited by 30
Patient-Derived In Vitro Models of Microglial Function and Synaptic Engulfment in Schizophrenia
Sheridan, S. D., Horng, J. E., & Perlis, R. H. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.01.004 · Cited by 30
Inglese, M., & Petracca, M. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.04.040 · Cited by 27
Yamamoto, S., Ohta, N., Matsumoto, A., et al. (2016) · Medical Science Monitor · doi:10.12659/msm.895739 · Cited by 26
Calabrò, M., Drago, A., Sidoti, A., Alessandro, S., & Crisafulli, C. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.06.013 · Cited by 25
Antiviral Inflammation during Early Pregnancy Reduces Placental and Fetal Growth Trajectories
Baines, K. J., Rampersaud, A. M., Hillier, D. M., Jeyarajah, M. J., Grafham, G. K., Eastabrook, G. D. M., Lacefield, J. C., & Renaud, S. J. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900888 · Cited by 25
Mundorf, A., Kubitza, N., Hünten, K., Matsui, H., Juckel, G., Ocklenburg, S., & Freund, N. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113504 · Cited by 25
Repositioning of the antipsychotic drug TFP for sepsis treatment
Park, J. H., Park, H. J., Lee, S. E., Kim, Y. S., Jang, G.-Y., Han, H. D., Jung, I. D., Shin, K. C., Bae, Y. M., Kang, T. H., et al. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01762-4 · Cited by 24
Ventura, J., McEwen, S. C., Subotnik, K. L., Hellemann, G., Ghadiali, M., Rahimdel, A., Seo, M. J., Irwin, M. R., & Nuechterlein, K. H. (2020) · Early Intervention in Psychiatry · doi:10.1111/eip.12946 · Cited by 24
Mata, I. F., Crespo‐Facorro, B., Pérez‐Iglesias, R., Carrasco-Marı́n, E., Arranz, M. J., Pelayo‐Terán, J. M., Leyva‐Cobián, F., & Vázquez‐Barquero, J. L. (2006) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30405 · Cited by 22
Miyazawa, A., Kanahara, N., Kogure, M., Otsuka, I., Okazaki, S., Watanabe, Y., Yamasaki, F., Nakata, Y., Oda, Y., Hishimoto, A., et al. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-07019-z · Cited by 22
de Bartolomeis, A., Iasevoli, F., Tomasetti, C., & Buonaguro, E. F. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8962-8 · Cited by 21
Self-citationMartins‐de‐Souza, D., Solari, F. A., Guest, P. C., et al. (2015) · Schizophrenia · doi:10.1038/npjschz.2015.50 · Cited by 21
Buonaguro, E. F., Tomasetti, C., Chiodini, P., Marmo, F., Latte, G., Rossi, R., Avvisati, L., Iasevoli, F., & de Bartolomeis, A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116658987 · Cited by 21
Self-citationMoyer, C. E., Erickson, S. L., Fish, K. N., Thiels, E., Penzes, P., & Sweet, R. A. (2015) · Cerebral Cortex · doi:10.1093/cercor/bhv040 · Cited by 20
Rimessi, A., Pavan, C., Ioannidi, E., Nigro, F., Morganti, C., Brugnoli, A., Longo, F., Gardin, C., Ferroni, L., Morari, M., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.20 · Cited by 20
Suzuki, T., Kametani, K., Weiheng, G., & Li, W. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14254 · Cited by 20
Aytaç, H. M., Özdilli, K., Tunçel, F. C., Pehlıvan, M., & Pehlıvan, S. (2020) · Immunological Investigations · doi:10.1080/08820139.2020.1832115 · Cited by 20
A pivotal role of nonmuscle myosin II during microglial activation
Janßen, S., Gudi, V., Prajeeth, C. K., Singh, V., Stahl, K., Heckers, S., Skripuletz, T., Pul, R., Trebst, C., Tsiavaliaris, G., et al. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.08.010 · Cited by 17
Reversal learning impairments in the maternal immune activation rat model of schizophrenia.
Kleinmans, M., & Bilkey, D. K. (2018) · Behavioral Neuroscience · doi:10.1037/bne0000275 · Cited by 17
Concordance of Immune-Related Markers in Lymphocytes and Prefrontal Cortex in Schizophrenia
Gatta, E., Saudagar, V., Drnevich, J. M., Forrest, M. P., Auta, J., Clark, L. V., Sershen, H. W., Smith, R. C., Grayson, D. R., Davis, J. M., et al. (2021) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgab002 · Cited by 17
Microglial Activation and the Onset of Psychosis
Cannon, T. D. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15111377 · Cited by 16
Kadasah, S., Arfin, M., Rizvi, S., Al-Asmari, M. M., & Al-Asmari, A. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s131144 · Cited by 15
Gross, A., Joffe, G., Joutsiniemi, S.-L., et al. (2003) · Neuropsychobiology · doi:10.1159/000070012 · Cited by 14
Zhao, L., Li, Y., Xu, T., et al. (2022) · Molecular Medicine · doi:10.1186/s10020-022-00431-6 · Cited by 14
Blood plasma proteomic modulation induced by olanzapine and risperidone in schizophrenia patients
Garcia, S., Carvalho, B. S., Guest, P. C., Steiner, J. H., & Martins‐de‐Souza, D. (2020) · Journal of Proteomics · doi:10.1016/j.jprot.2020.103813 · Cited by 13
CRMP-5 interacts with tubulin to promote growth cone development in neurons.
Ji, Z., Tan, M., Gao, Y., et al. (2014) · PubMed · Cited by 12
Turano, A., McAuley, E. M., Muench, M. C., & Schwarz, J. M. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113449 · Cited by 11
Pubertal LPS treatment selectively alters PSD-95 expression in male CD-1 mice
Kolmogorova, D., & Ismail, N. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.07.025 · Cited by 11
O’Connell, K. E., Thakore, J. H., & Dev, K. K. (2015) · Cytokine · doi:10.1016/j.cyto.2014.11.003 · Cited by 10
The Role of Homer1b/c in Neuronal Apoptosis Following LPS-Induced Neuroinflammation
Cui, Z., Zhou, L., Liu, C., Zhu, G., Wu, X., Yan, Y., Xia, X., Ben, Z., Song, Y., Zhou, Y., et al. (2014) · Neurochemical Research · doi:10.1007/s11064-014-1460-6 · Cited by 10
Pharmacological and proteomic analyses of neonatal polyI:C-treated adult mice
Kitagawa, K., Nagai, T., & Yamada, K. (2018) · Neuroscience Research · doi:10.1016/j.neures.2018.10.007 · Cited by 10
Allimuthu, P., Nandeesha, H., Chinniyappan, R., Bhardwaz, B., & Jesudas, B. R. (2020) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-020-00880-y · Cited by 10
Pierre, W. C., Londoño, I., Quiniou, C., Chemtob, S., & Lodygensky, G. A. (2022) · International Journal of Developmental Neuroscience · doi:10.1002/jdn.10179 · Cited by 10
Buchtová, H., Fajnerová, I., Stuchlı́k, A., & Kubík, Š. (2016) · Hippocampus · doi:10.1002/hipo.22678 · Cited by 8
Howes, O. D., Cummings, C., & Heurich, M. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.08.014 · Cited by 3
Research works printed but not linked: 2
- Li R, Ma X, Wang G, Yang J, Wang C (2016) Why sex differences in schizophrenia? J transl neuroscience 1(1):37–42
- Müller N 2010 COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Current opinion in investigational drugs (London, England : 2000) 11 (1):31–42
Cited by
Sorted by citations
De Simone, G., Mazza, B., Vellucci, L., Barone, A., Ciccarelli, M., & de Bartolomeis, A. (2023) · Antioxidants · doi:10.3390/antiox12040975 · Cited by 49
Self-citationLiu, Y., Ren, H., Zhang, Y., Deng, W., Ma, X., Zhao, L., Li, X., Sham, P., Wang, Q., & Li, T. (2024) · Psychological Medicine · doi:10.1017/s003329172400014x · Cited by 15
Brain structure in schizophrenia: what do we know and what next?
Lawrie, S. M. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00172-5 · Cited by 7
Sheaves, B., Cropley, V. L., Moseley, P., Woodruff, P. W. R., Punton, G., Speth, C., Speth, J., Meerlo, P., & Brederoo, S. G. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf107 · Cited by 6
Metadata
- Authors
- de Bartolomeis, A., Barone, A., Vellucci, L., Mazza, B., Austin, M. C., Iasevoli, F., & Ciccarelli, M.
- Affiliations
- Federico II University Hospital (IT)
- Idaho State University (US)
- Venue
- Molecular Neurobiology
- Published
- 2022-08-13
- Volume
- 59
- Issue
- 10
- Pages
- 6460-6501
- ISSN
- 0893-7648 (ISSN-L)
- 1559-1182
- PMC
- PMC9463235
- OpenAlex
- W4291237996
- Cited by
- 113
- References
- 325
- Citations by year
- 2026: 31 · 2025: 30 · 2024: 33 · 2023: 15 · 2022: 4
- FWCI
- 1.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Molecular Neurobiology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Università degli Studi di Napoli Federico II
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- schizophrenia, inflammation, dopamine-glutamate interaction, dendritic spines, postsynaptic density, NMDA receptor, microglia, maternal immune activation, kynurenine pathway, plasma inflammatory markers, functional connectivity, cognitive impairment, antipsychotic resistance, clozapine, translational research
- MeSH terms
- Dopamine, Humans, Inflammation, Schizophrenia, Antipsychotic Agents, Receptors, N-Methyl-D-Aspartate, Glutamic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review